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Abstract: Expression of aquaporin-1 (AQP1) in endothelial cells is critical for their migration and
angiogenesis in cancer. We tested the AQP1 inhibitor, bacopaside II, derived from medicinal plant
Bacopa monnieri, on endothelial cell migration and tube-formation in vitro using mouse endothelial
cell lines (2H11 and 3B11) and human umbilical vein endothelial cells (HUVEC). The effect of
bacopaside II on viability, apoptosis, migration and tubulogenesis was assessed by a proliferation
assay, annexin-V/propidium iodide flow cytometry, the scratch wound assay and endothelial
tube-formation, respectively. Cell viability was reduced significantly for 2H11 at 15 µM (p = 0.037),
3B11 at 12.5 µM (p = 0.017) and HUVEC at 10 µM (p < 0.0001). At 15 µM, the reduced viability
was accompanied by an increase in apoptosis of 38%, 50% and 32% for 2H11, 3B11 and HUVEC,
respectively. Bacopaside II at ≥10 µM significantly reduced migration of 2H11 (p = 0.0002) and
3B11 (p = 0.034). HUVECs were most sensitive with a significant reduction at ≥7.5 µM (p = 0.037).
Tube-formation was reduced with a 15 µM dose for all cell lines and 10 µM for 3B11 (p < 0.0001).
These results suggest that bacopaside II is a potential anti-angiogenic agent.
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1. Introduction
Angiogenesis is critical for the continuing growth and progression of solid tumours and is largely
driven by tumour production of vascular endothelial growth factor (VEGF) to stimulate endothelial
cell proliferation [1]; the process is also critically dependent on the migration of endothelial cells
to form the new vascular networks (reviewed in [2]). Cell migration involves rapid changes in cell
volume and shape mediated by the transmembrane protein aquaporin-1 (AQP1), which allows water
flow across the plasma membrane in response to osmotic gradients created by ion transport and actin
de-polymerization. Water (and ion) influx through AQP1 can increase hydrostatic pressure and is
proposed to cause local expansion of the plasma membrane, followed by actin re-polymerization to
stabilise the cell membrane protrusion [3]. The increased permeability is important in allowing actin
remodelling and cytoskeleton rearrangement required for migrating cells [4]. AQP1 is over-expressed
in many human cancers including those of breast, colon and prostate and was shown to be a prognostic
marker for poorer survival outcome in colon cancer patients (reviewed in [5]). Previously, we reported
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AQP1 over-expression in a proportion of patients’ colorectal cancer tumours compared to matched
normal mucosa, with the highest AQP1 expression in the endothelial cells of the microvessels in
colon tumour tissue. This was consistent with higher AQP1 expression in human umbilical vein
endothelial cells (HUVECs) compared to colon cancer epithelial cell lines [6]. We have also shown
that pharmacological inhibition of AQP1 results in impaired migration, invasion and tubulogenesis
in vitro [6]. Evidence is thus accumulating based on our own work and others [5] to suggest that AQP1
is a prime target for anti-cancer therapy.
Extracts from the plant Bacopa monnieri have long been used in traditional Hindu medicine for
improving memory and treating anxiety and epilepsy [7]. We previously examined a purified extract
from this medicinal plant, bacopaside II, and showed using the Xenopus oocyte expression system that
it specifically blocked AQP1-mediated water transport [8]. We also found that it significantly reduced
migration of a colon cancer cell line expressing relatively high levels of AQP1 [8].
The anti-angiogenesis drugs bevacizumab and aflibercept, in combination with chemotherapy
and regorafenib as monotherapy, have shown improved progression-free survival and overall survival
in several phase III trials [9–12]. However a significant number of patients do not achieve any
meaningful benefit from this VEGF-targeted therapy. This could in large part be due to inherent
resistance mechanisms that allow cancers to evade the effects of VEGF inhibition, or via induced release
of compensatory pro-angiogenic factors (reviewed in [13,14]): alternative types of anti-angiogenic
therapies are thus required. This is the first study to investigate the effects of bacopaside II on
endothelial cell migration and tubulogenesis and provides evidence that bacopaside II is a potential
anti-angiogenic therapy for the treatment of cancer.
2. Results
2.1. Endothelial Cells Express the Bacopaside II Target AQP1
AQP1 was expressed in all three endothelial cell lines, 2H11, 3B11 and HUVEC, as determined by
Western immunoblot. The molecular weight was approximately 55 kDa, consistent with post-translational
modification (glycosylation) [15] (Figure 1A). Relative levels of AQP1 expression were similar between
the cell lines at 1.0, 1.23 and 0.78 for 2H11, 3B11 and HUVEC, respectively (Figure 1B).
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Figure 1. AQP1 expression in endothelial cell lines. (A) Western immunoblot confirming AQP1 
protein expression in mouse endothelial cell lines 2H11 and 3B11 and human endothelial cell line 
HUVEC; (B) Quantification of AQP1 bands in (A), standardized relative to 2H11 and normalised to 
total protein. 
2.2. Bacopaside II Reduced Endothelial Cell Viability and Increased Apoptosis  
Bacopaside II induced a dose-dependent reduction in cell viability for all three endothelial cell 
lines (Figure 2). There was a significant decrease in cell viability compared to the vehicle control at 
15 μM for 2H11 cells (83% viability, p = 0.037), at 12.5 μM (87% viability, p = 0.017) and 15 μM (70% 
viability, p < 0.0001) for 3B11 cells and at 10 μM (52% viability), 12.5 μM (39% viability) and 15 μM 
(28% viability) for HUVECs (p < 0.0001). 
Figure 1. AQP1 expression in endothelial cell lines. (A) Western immunoblot confirming AQP1 protein
expression in mouse endothelial cell lines 2H11 and 3B11 and human endothelial cell line HUVEC;
(B) Quantification of AQP1 bands in (A), standardized relative to 2H11 and normalised to total protein.
2.2. Bacop side II Reduced Endothelial Cell Viability creased Apopto is
Bacopaside II induced a dose-dependent reduction in cell viability for all three endothelial cell
lines (Figure 2). There was a significant decrease in cell viability compared to the vehicle control
at 15 µM for 2H11 cells (83% viability, p = 0.037), at 12.5 µM (87% viability, p = 0.017) and 15 µM
(70% viability, p < 0.0001) for 3B11 cells and at 10 µM (52% viability), 12.5 µM (39% viability) and
15 µM (28% viability) for HUVECs (p < 0.0001).
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Figure 2. Bacopaside II decreased viability. Cells were treated with bacopaside II for 20 h, and viability 
was determined by the MTS assay. Data are shown as the mean ± SD (n = 6 per treatment group). 
Asterisks represent significant differences relative to the vehicle control (* p < 0.05; **** p < 0.0001). 
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measured to determine whether this accounted for the reduction in cell viability at higher 
concentrations. Apoptosis was determined following 8 h of treatment with bacopaside II to 
correspond to similar time points monitored in the wound closure assay. There was a dose-
dependent increase in the number of cells undergoing apoptosis (early and late) for both mouse 
endothelial cell lines and HUVECs (Figure 3). The increase in apoptosis with 10, 12.5 and  
15 μM bacopaside II relative to that with vehicle was 3%, 12% and 38%, for 2H11 (Figure 3A,B), 1%, 
22% and 50% for 3B11 (Figure 3C,D) and 6%, 7% and 32% for HUVEC (Figure 3E,F).  
 
Figure 3. Bacopaside II increased endothelial cell apoptosis as determined by flow cytometry. 
Histograms (left) show percentages of apoptotic cells (early and late) in a representative experiment 
for data shown in the scatter plots at the different concentrations of bacopaside II. Results are shown 
for 2H11 (A,B), 3B11 (C,D) and HUVEC (E,F). In (A,C,E), results shown as the mean ± SD; in (B,D,F), 
scatter plots show population gates of viable cells (left lower quadrant), or cells either in early 
apoptosis (right lower quadrant), late apoptosis (right upper quadrant), or necrosis (left upper 
quadrant). 
2.3. Endothelial Cell Morphology Was Altered by Bacopaside II 
Treatment with bacopaside II induced similar morphological changes in all three endothelial cell 
lines (Figure 4). Large intracellular vacuoles were evident at concentrations of bacopaside II that 
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Asterisks represent significant differences relative to the vehicle control (* p < 0.05; **** p < 0.0001).
The proportion of cells undergoing apoptosis following treatment with bacopaside II was
measured to determine whether this accounted for the reduction in cell viability at higher
concentrations. Ap ptosis was determined following 8 of treatment with bacopasid II to corre pond
to similar tim points monitor d in the wound closure assay. There w s a dose-d pendent increase in
the number of cells undergoing apoptosis (early and late) for both mouse endothelial cell lines and
HUVECs (Figure 3). The increase in apoptosis with 10, 12.5 and 15 µM bacopaside II relative to that
with vehicle was 3%, 12% and 38%, for 2H11 (Figure 3A,B), 1%, 22% and 50% for 3B11 (Figure 3C,D)
and 6%, 7% and 32% for HUVEC (Figure 3E,F).
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2.3. Endothelial Cell Morphology Was Altered by Bacopaside II
Treatment with bacopaside II induced similar morphological changes in all three endothelial
cell lines (Figure 4). Large intracellular vacuoles were evident at concentrations of bacopasid II that
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induced a decline in cell viability, ≥12.5 µM for 2H11 and 3B11 and ≥10 µM for HUVEC, but also at
doses that did not reduce cell viability, 10 µM for 2H11 and 3B11 and 7.5 µM for HUVEC.
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2.4. Endothelial Cell Migration Was Reduced by Bacopaside II
We assessed the effects of various concentrations of bacopaside II on endothelial cell migration
in a scratch wound assay. Figure 5 shows a dose-dependent slowing of migration with bacopaside
II for all three endothelial cell lines. This as significant for 2H11 at 10, 12.5 and 15 µM with 72%
(p = 0.0002), 40% (p < 0.0001) and 15% (p < 0.0001) sure respectively compared to 88% with vehicle.
The 3B11 line behaved similarly with closure of 78% (p = 0.034), 35% (p < 0.0001) and 0% (p < 0.0001)
at 10, 12.5 and 15 µM compared to 95% with vehicle. The human endothelial cell line HUVEC was
most sensitive to the effects of bacopaside II with closure of 81% (p = 0.037), 44% (p < 0.0001), 27%
(p < 0.0001) and 15% (p < 0.0001) at 7.5, 10, 12.5 and 15 µM as compared to 99% closure with vehicle.
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Figure 5. Endothelial cell migration was inhibited by bacopaside II. Wound area for 2H11, 3B11 and
HUVEC was measured using NIS-Elements software (Nikon, Tokyo, Japan) and the percentage closure
calculated relative to that at Time 0 for each cell line. Data are the mean ± SD of six replicates from a
representative experiment. p-values are for closure relative to vehicle at 12 h, determined by one-way
ANOVA with the Bonferroni test (* p < 0.05); *** p ≤ 0.0002; **** p < 0.0001).
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2.5. Bacopaside II Inhibited Endothelial Cell Tube Formation
We used an in vitro tube-formation assay to assess the anti-angiogenic potential of bacopaside II.
Tube-forming ability, as measured by the number of loops assembled, was significantly reduced
compared to vehicle with 15 µM bacopaside II for 2H11 (vehicle, 69 loops; 15 µM, 3 loops)
(Supplementary Data), with both 10 and 15 µM for 3B11 (vehicle, 74 loops; 10 µM, 33 loops; 15 µM,
3 loops) and with 15 µM for HUVECs (vehicle, 24 loops; 15 µM, 3 loops; p < 0.0001) (Figure 6A).
Representative images for 3B11 after 2–3 h of treatment (Figure 6B) show that cells treated with 10 µM
bacopaside II clustered into small aggregates without any capacity to form tubes.
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Figure 6. Endothelial cell tube formation was inhibited by bacopaside II. (A) 2H11, 3B11 and HUVEC
were treated with 0, 10, or 15 µM bacopaside II for 2–3 h (2H11 and 3B11) or 20 h (HUVEC) and the
number of loops counted. Data are the mean ± SD of six replicates from two independent experiments.
Asterisks represent p-values relative to the vehicle control (**** p < 0.0001). (B) Representative images
of 3B11 on matrigel-coated plates treated with 0 and 10 µM bacopaside II.
Since the 15 µM dose reduced viability and increased apoptosis, we further investigated tube
formation at lower doses of bacopaside II. Unlike results for 3B11, doses of bacopaside II of 10 µM for
2H11 and 7.5 µM for HUVEC had no effect on tube formation despite significantly slowing migration.
We considered that bacopaside II had insufficient time to have its effect on these cells due to the
rapidity of the tube formation assay. Since the MTS assay showed that after 20 h of treatment, there
was no significant loss of cell viability at these concentrations, we pre-treated 2H11 with 10 µM and
HUVEC with 7.5 µM bacopaside II for 20 h and used these cells in tube formation assays with the
same dose of bacopaside II. Pre-treated cells failed to form tubes with these doses, while cells that only
received the treatment for the duration of the assay did form tubes (Figure 7). This confirmed that
bacopaside II could inhibit tube formation independently of inducing apoptosis and needed time to
cross the cell membrane to access the intra-cellular binding site of AQP1.
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formation, many act by inducing vascular endothelial cell apoptosis as demonstrated both in vitro 
Figure 7. Lower concentratio s of bacopaside II inhibited othelial tube formation of 2H11 and
HUVEC after pre-treatment with the drug. 2H11, and HUVEC were cultured in either normal medium
or were pre-treated for 20 h with bacopaside II at 0 and 10 µM for 2H11 or 7.5 µM for HUVEC. Untreated
and pre-treated cells, resuspended either in vehicle or bacopaside II, were used in the tube formation
assay and the number of loops counted. Data are the mean ± SD from two independent experiments
(n = 6). Aste isks repres nt p-values for bacopaside treated cells without pre-trea ment relative to with
pre-treatment (**** p < 0.0001) (two-way ANOVA with the Bonferroni test).
3. Discussion
This is the first study to assess the anti-angiogenesis potential of the AQP1 inhibitor bacopaside II.
We assessed its effects on cell viability, apoptosis, morphology, migration and tube-forming ability in
mouse endothelial cell lines 2H11 and 3B11 and human endothelial cell line HUVEC. In summary, both
mouse endothelial cell lines showed increased apoptosis, reduced migration and significant inhibition
of tube-formati n at 15 µM. At 10 µM, there was no loss of vi bility and no significant induction of
apoptosis, yet migration was inhibited, and for 3B11, tubulogenesis was also inhibited. 2H11 cells
required pre-treatment with 10 µM bacopaside II to show inhibition of tubulogenesis. HUVECs were
the most sensitive showing reduced viability, increased apoptosis and inhibited migration at 10, 12.5
and 15 µM and inhibi ion of tubulogenesis at 15 µM. n HUVECs, m gration was r duced even at
7.5 µM, with no loss of viability, and following 20 h of pre-treatme t, tube formation was also inhibited.
The results of this study suggest that bacopaside II is a potential anti-angiogenesis therapy; it is
effective at reducing endothelial cell migration and tube formation at doses below those that induce cell
death. This is consistent with our previous work showing that AQP1 activity and HT29 colon cancer
cell migration w re signific ntly blocked at concentrations that did not significantly reduc viability
over 24 h [6,8]. In addition to the apoptosis-inducing activity of bacopaside II, we found that treatment
of 2H11 and HUVEC with a non-cytotoxic dose of bacopaside II inhibited tube formation, provided
cells had adequate length of exposure to the agent. The requirement for pre-treatment suggests that
there is a latency period, which could be the time for bac side II to transit across the cell membrane
to access the proposed intrac llular binding site on AQP1. In additi n, we have found that bacopaside
II was predicted to have the most favourable binding energy at a position occluding the cytoplasmic
side of the AQP1 water pore; this was not the case for AQP4 [8], and we are currently analysing
the binding probabilities of other AQPs. Bacopaside II and other active constituents of B. monnieri
extract are repor ed to modulate the acti ity of P-glycoprot in (P-gp), n this interaction may alter the
bio-availability of any P-gp substrate drug, a point to be considered for co-administration in vivo [16].
While anti-angiogenic drugs may inhibit angiogenesis by targeting any of the steps involved
in neovascularisation including degradation of extracellular matrix, migration, proliferation or tube
formation, many act by inducing vascular endothelial cell apoptosis as demonstrated both in vitro and
in vivo [17–20]. Others have shown that certain anti-angiogenic inhibitors can induce autophagy [19,20].
Here, we show that blocking AQP1 with bacopaside II induces apoptosis in a dose-dependent manner
and provide the first evidence that morphological changes induced by bacopaside II are consistent with
the appearance of autophagic vacuoles. Currently-used anti-angiogenic drugs, such as bevacizumab,
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target the vascular endothelial growth factor (VEGF) signalling pathway and have become a mainstay in
the treatment of malignant disease. However, despite a number of randomised clinical trials showing
a clinical benefit of anti-VEGF drugs in combination with chemotherapy [21,22], many patients do not
respond, and others become resistant to such therapy [23]. Furthermore, VEGF inhibition may lead to
a more invasive phenotype with an increased number of metastases [24]. Since aquaporins play roles
in transcellular fluid transport and cell migration, it is reasonable to consider whether inhibiting AQP1
would be expected to have problematic side-effects. However, in the very rare human cases where there
is an inherited bi-allelic inactivating mutation in AQP1, the only clinical consequence is an impaired
renal concentrating ability, which would be a concern only in conditions of dehydration [25,26]. Thus,
AQP1 presents as a plausible therapeutic target, which could be acted upon to decrease potential for
metastasis while not contributing to widespread effects in other tissues. The current study provides a
strong foundation for future in vivo investigations that will evaluate whether bacopaside II could be used
clinically as an anti-angiogenic therapy for cancer patients.
4. Materials and Methods
4.1. Cell Lines and Cell Culture
The mouse endothelial cell lines 2H11 and 3B11 were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA) and maintained in complete medium of DMEM with 10% foetal
calf serum (FCS) (Equitech-Bio, Inc., Kerrville, TX, USA), 1% penicillin-streptomycin (Life Technologies,
Grand Island, NY, USA) and 1% glutamax (Life Technologies). Human umbilical vein endothelial cells
(HUVEC) (PromoCell, Heidelberg, Germany) were cultured in endothelial growth medium (In vitro
Technologies, Noble Park North, VIC, Australia) according to the supplied protocol.
4.2. Analysis of AQP1 Expression by Western Immunoblot
Whole-cell lysates were prepared, and 20 µg of protein were resolved by denaturing electrophoresis
on 12% Mini- Protean TGX precast polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA, USA),
transferred by the Trans-Blot Turbo Transfer System (Bio-Rad) and immune-stained using 1:1000
rabbit anti-human AQP1 polyclonal IgG (ab168387, Abcam, Cambridge, UK). Immunoreactivity was
detected using the appropriate horseradish peroxidase-conjugated IgG and visualized using enhanced
chemiluminescence (Bio-Rad). Bands were quantified relative to total protein loaded using Image Lab
software (Bio-Rad).
4.3. MTS Viability Assay
Endothelial cells were seeded in complete medium (2H11 and 3B11) or endothelial growth
medium (HUVEC) at 1 × 104 cells per well of a 96-well plate and were incubated overnight. Cells were
treated with various concentrations of bacopaside II for 20 h. The cell viability was determined using
the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA)
according to the manufacturer’s instructions and absorbance read at 492 nm. Results were calculated
as the mean absorbance normalized to the vehicle control.
4.4. Apoptosis Assay
Cells (1 × 105) were seeded in six-well plates and left for 48 h to reach confluence. Apoptosis
controls were treated with paclitaxel (400 nM) for 24 h prior to the Time 0 collection. Necrosis controls
were prepared by heating harvested cells to 63 ◦C for 30 min. Cells were treated either with medium
(untreated), vehicle (1% methanol) or 10, 12.5 or 15 µM bacopaside II. Cells were collected at 0 and
6 h after treatment, stained with the Annexin-V-FLUOS staining kit (Roche Diagnostics, Mannheim,
Germany) as per the manufacturer’s instructions and run on the BD FACSCanto II cell analyser
(BD Biosciences, San Jose, CA, USA). Gating with cell doublet exclusion and analysis was performed
using FlowJo software v 10.4.
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4.5. Scratch Wound (Migration) Assay
Cells were seeded according to growth rate at either 1 × 104 per well for 2H11, 4 × 104 for
3B11 or 6 × 104 per well for HUVEC in 96-well plates in their respective medium for 6 h and
then serum starved overnight in medium with just 2% FCS and including 1 µg/mL mitomycin C
(Sigma, St. Louis, MO, USA) (the mix referred to herein as “mitomedium”), to inhibit cell proliferation.
The following day, a circular wound was made in the cell monolayer with a p10 pipette tip. Loose cells
were removed and medium replaced with fresh mitomedium for 1 h followed by replacement with
treatment, either vehicle (1% methanol) or various concentrations of bacopaside II in mitomedium.
Cells were monitored every 2 h with the area of wound closure determined at each time point.
4.6. Endothelial Tube Formation (Angiogenesis) Assay
Mouse endothelial cells or HUVECs were seeded onto a thin layer (10 µL) of matrigel in a
96-well angiogenesis µ-plate (Ibidi, Martinsried, Germany) at 1.5 × 104 cells per well either in vehicle
(1% methanol) or bacopaside II at 10 or 15 µM made in complete medium (2H11 and 3B11) or
endothelial growth medium (HUVEC). The numbers of loops formed were counted at peak tube
formation, 2–3 h for mouse endothelial cells and 20 h for HUVECs. For pre-treatment experiments,
cells were either cultured in normal medium, or pre-treated with vehicle or bacopaside II at lower
concentrations, 10 µM for 2H11 and 7.5 µM for HUVEC, followed by harvesting of cells, resuspension
in vehicle or bacopaside II and seeding on matrigel, with loops counted at peak formation time
as before.
4.7. Statistical Analysis
The numerical data are presented as the means ± standard deviation. Cell viability, wound
closure and tube formation assays were analysed by ANOVA with the Bonferroni post-hoc test.
5. Conclusions
The results show that bacopaside II significantly inhibits migration and angiogenesis of mouse
and human endothelial cells and induces apoptosis. These actions of bacopaside II may be mediated
by the blocking of aquaporin 1 activity and require further investigation both in vitro and in vivo.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/3/
653/s1.
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